Search Results
Aug 26, 2025, 09:00 ET AliveDx registra MosaiQ® como dispositivo exento de Clase II
de Sjögren, ESC) en un microarray.AiPlex ® CD* – Panel de enfermedad celíaca (5 marcadores) que combina marcadores IgA e IgG en un microarray.AiPlex ® VAS* – Panel de vasculitis (3 marcadores), marcadores de autoanticuerpos clave: MPO,
More news about: AliveDx Suisse SA
Aug 18, 2025, 09:00 ET Ping Identity Unveils Just-in-time Privileged Access Capability to Empower Enterprises Across the Full Identity Lifecycle
Platform, offering comprehensive capabilities across all three categories of identity: Access Management (AM), Identity Governance and Administration (IGA), and Privileged Access Management (PAM). Using centralized identity controls in a single platform, this trifecta empowers customers with a more comprehensive
More news about: Ping Identity
Aug 12, 2025, 11:02 ET KeyData Cyber Acquires BeyondID to Create a Powerhouse in Identity Security
identity leaders to form a pure-play powerhouse in total identity security. The combined team brings unmatched depth and breadth across IAM, CIAM, PAM and IGA, with more than 200 identity experts and a proven track record for delivering complex programs for mid-market and enterprise customers across the private
More news about: KeyData Cyber
Aug 11, 2025, 09:00 ET GC Biopharma Announces Publication Demonstrating 14-Day Stability of Pooled ALYGLO® Under Refrigerated Conditions
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately
More news about: GC Biopharma USA Inc.
Aug 11, 2025, 07:00 ET Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
degrader initially being developed to target Gd-IgA1, the aberrant immunoglobulin that drives IgA Nephropathy. In the Phase 1 study, a single dose of BHV-1400 was subcutaneously administered at a dose of 500 mg and achieved rapid, deep and sustained reductions in Gd-IgA1 of up to 81%, with a median reduction
More news about: Biohaven Ltd.
Aug 06, 2025, 07:23 ET Manipal Hospital Varthur Hosts Breastfeeding Awareness Event to Guide Families Through Early Parenthood
initial days, breastmilk is secreted in the form of a rich, yellow liquid known as colostrum, which is packed with antibodies, particularly secretory IgA. These antibodies coat the baby's intestinal wall, helping to strengthen the immune system and prevent infections. Skin-to-skin contact is also essential
More news about: Manipal Hospitals
Aug 06, 2025, 01:09 ET 雲頂新耀宣布耐賦康®在中國台灣地區獲完全批准，適應症中無基線蛋白尿水平限制
性。耐賦康®專為IgA腎病患者研制，每顆膠囊含布地奈德4mg，通過特殊的遲釋及緩釋雙重制劑工藝，將布地奈德三層包衣微丸靶向釋放於回腸末端的黏膜B細胞（包括派爾集合淋巴結），三層包衣微丸持續穩定釋放布地奈德，高濃度覆蓋整個靶區域，從而減少誘發IgA腎病的半乳糖缺陷的IgA1（Gd-IgA1）產生，進而干預發病機制上游階段，達到治療IgA腎病的作用。 2019年6月，雲頂新耀與Calliditas Therapeutics 簽訂獨家授權許可協議，獲得在大中華地區和新加坡開發以及商業化耐賦康®的權利。該協議於2022年3月擴展，將韓國納入雲頂新耀的授權許可范圍。
More news about: 雲頂新耀
Aug 01, 2025, 16:20 ET WhereverFamily Announces Winners of Eighth Annual Awards
Ocean City, Maryland iGA Istanbul Airport
More news about: WhereverFamily
Aug 01, 2025, 16:15 ET Trazeetravel.com Announces Winners of Its Annual Awards
Favorite Overall Airport in the World iGA Istanbul Airport Fourth Consecutive Year
More news about: Trazee Travel
Jul 30, 2025, 10:06 ET Transplant Therapeutics Consortium Receives FDA Notice of Reviewability for the iBox Scoring System Full Qualification Package
has historically been successful advancing new innovative therapies for HIV and cancer and most recently promoted the introduction of 4 new drugs for IgA nephropathy, a chronic kidney disease with no approved therapies 5 years ago before the use of proteinuria as a surrogate endpoint. About
More news about: American Society of Transplantation
Jul 30, 2025, 08:00 ET CDI Labs Launches Pan-isotype Analysis of Serum Autoantibodies to Unlock Critical New Insights Into Humoral Immunity
proteome (using HuProt™) or to most vertebrate viruses (using VirScan®). Comprehensive analysis options include detection of pan-IgA (IgA1 and IgA2), IgA1, IgA2, IgD, IgE, pan-IgG (IgG1, IgG2, IgG3 and IgG4), IgG1, IgG2, IgG3, IgG4 and IgM.
More news about: CDI LABORATORIES, INC.
Jul 24, 2025, 22:57 ET 雲頂新耀宣佈配售股份 擬集資約15.725億港元
N）等多種原發性腎小球疾病。其在原發性膜性腎病1b/2a期研究中展現出起效快、緩解持續、耐受性好、口服便捷等綜合優勢，有望為全球患者帶來更優治療選擇。 耐賦康®作為首個且唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物，自納入中國國家醫保目錄以來快速放量，已惠及超過兩萬名患者。公司亦正加快推進Gd-IgA1診斷試劑的轉化，致力打造覆蓋診斷、治療、長期管理的一體化IgA腎病疾病管理生態。 伊曲莫德（維適平®）在中國大陸的新藥上市申請也已獲受理，預計2025年底至2026年初獲批，其新藥上市申請也已獲韓國受理。伊曲
More news about: 雲頂新耀
Jul 21, 2025, 08:00 ET Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
Results from the Phase 3 ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 studies, that further reinforced the overall efficacy profile met co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16. Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to deucravacitinib
More news about: Johnson & Johnson
Jul 16, 2025, 09:00 ET GC Biopharma Presents New Viscosity Research on IVIG Products at ISTH 2025
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately
More news about: GC Biopharma USA Inc.
Jul 02, 2025, 08:00 ET Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported in association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal
More news about: Hikma Pharmaceuticals USA Inc.
Jul 01, 2025, 13:00 ET UAG será sede del 3er Foro Mundial de Relaciones Públicas, Protocolo y Eventos
Protocolo, la Universidad de Guadalajara, la Universidad Autónoma de Guadalajara, e IGA Comunicación Total Consultores. Esta tercera edición del foro ofrecerá 8 conferencias, 1 panel y 16 horas de actividades con expertos internacionales
More news about: Universidad Autónoma de Guadalajara
Jun 27, 2025, 09:00 ET GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately
More news about: GC Biopharma USA Inc.
Jun 26, 2025, 08:00 ET Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
diversified and balanced pipeline of drug candidates targeting a range of renal indications, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD). Alebund has
More news about: Alebund Pharmaceuticals
Jun 25, 2025, 20:38 ET BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
SC0062 for the treatment of diabetic kidney disease (DKD) with albuminuria. This marks the second BTD for SC0062, following its initial designation for IgA nephropathy (IgAN) with proteinuria, which is conducting in Phase III, underscoring the compound's transformative potential across multiple chronic kidney
More news about: BioCity Biopharma
Jun 24, 2025, 17:31 ET BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight
IgA Nephropathy Market IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease,
More news about: DelveInsight Business Research, LLP
Jun 23, 2025, 08:03 ET Omada and iC Consult Strengthen Two-Decade Partnership to Drive Identity Governance Innovation
June 23, 2025 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced a renewed strategic focus on its long-standing partnership with iC Consult, the leading independent consultancy, systems integrator,
More news about: Omada
Jun 23, 2025, 03:03 ET Omada and iC Consult Strengthen Two-Decade Partnership to Drive Identity Governance Innovation
June 23, 2025 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), today announced a renewed strategic focus on its long-standing partnership with iC Consult, the leading independent consultancy, systems integrator,
More news about: Omada
Jun 23, 2025, 02:03 ET Omada und iC Consult verstärken 20-jährige Partnerschaft für weitere Innovationen im Bereich IGA
23. Juni 2025 /PRNewswire/ -- Omada A/S (Omada"), ein weltweit führender Anbieter von Identity Governance und Administration (IGA), gab heute eine neue strategische Ausrichtung seiner langjährigen Partnerschaft mit iC Consult bekannt, dem führenden unabhängigen Berater, Systemintegrator
More news about: Omada
Jun 23, 2025, 02:03 ET Omada e iC Consult refuerzan su asociación de dos décadas
23 de junio de 2025 /PRNewswire/ -- Omada A/S ("Omada"), líder mundial en Gobierno y Administración de Identidades (IGA), ha anunciado hoy un renovado enfoque estratégico en su larga asociación con iC Consult, consultora independiente líder, integradora de sistemas y proveedora
More news about: Omada
Jun 11, 2025, 23:07 ET Automation Anywhere informa de fuerte crecimiento y rentabilidad en primer trimestre del año fiscal 2026
industria y cuatro nuevas soluciones de IA agéntica, lo que representa un paso significativo hacia la habilitación de la inteligencia general artificial (IGA) en el trabajo. «Nuestro sólido rendimiento en el primer trimestre subraya la aceleración de la adopción global de nuestras soluciones de automatización
More news about: Automation Anywhere, Inc.